Stay updated on Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page.

Latest updates to the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe webpage has undergone significant updates, including the removal of detailed descriptions of a Phase II trial for Pembrolizumab in advanced lung cancer, while adding a new interventional model and a revision number update.SummaryDifference52%
- Check30 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to March 24, 2025.SummaryDifference0.2%
- Check37 days agoChange DetectedThe web page has been updated to include helpful links provided by the Spanish Lung Cancer Group, offering users more information about Fundación GECP studies. Additionally, the revision number has been updated from v2.14.2 to v2.14.3.SummaryDifference0.7%
- Check45 days agoChange DetectedThe webpage has been updated to reflect new results and definitions related to the efficacy of Pembrolizumab re-challenge for advanced NSCLC, including specific survival metrics and updated reporting dates. Additionally, some outdated information has been removed, including previous results and definitions.SummaryDifference16%
- Check73 days agoChange DetectedThe page has removed a notice about heavy traffic affecting certain services and products, as well as a message indicating that no results were posted. Additionally, a new entry stating 'Results Submitted' has been added.SummaryDifference1%
Stay in the know with updates to Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page.